Segment Information (Tables)

9 Months Ended

Sep. 30, 2022

Segment Reporting [Abstract]

Schedule of Financial Information by Segment

Financial information by segment for the three months ended September 30, 2022 and 2021 is as follows:

	Three Months Ended September 30, 2022
	Cell Therapy			BioBanking		Degenerative Disease			Other				Total
Net sales	$	-		$	1,405	$	2,730		$	-			$	4,135
Gross profit		-			506		(3,584	)		-				(3,078	)
Direct expenses		19,863			432		3,194			11,965				35,454
Segment contribution	$	(19,863	)	$	74	$	(6,778	)		(11,965	)			(38,532	)
Indirect expenses										(32,886	)	(a)		(32,886	)
Loss from operations													$	(5,646	)
(a) Components of other
Change in fair value of contingent consideration liability										(33,243	)
Change in fair value of contingent stock consideration										(196	)
Amortization										553
Total other									$	(32,886	)

	Three Months Ended September 30, 2021
	Cell Therapy			BioBanking			Degenerative Disease		Other				Total
Net sales	$	-		$	1,343		$	9,279	$	-			$	10,622
Gross profit		-			420			7,891		-				8,311
Direct expenses		22,690			505			2,601		19,613				45,409
Segment contribution	$	(22,690	)	$	(85	)	$	5,290		(19,613	)			(37,098	)
Indirect expenses										(47,996	)	(b)		(47,996	)
Income from operations													$	10,898
(b) Components of other
Change in fair value of contingent consideration liability										(48,549	)
Amortization										553
Total other									$	(47,996	)

Financial information by segment for the nine months ended September 30, 2022 and 2021 is as follows:

	Nine Months Ended September 30, 2022
	Cell Therapy			BioBanking			Degenerative Disease			Other				Total
Net sales	$	-		$	4,061		$	9,785		$	-			$	13,846
Gross profit		-			949			(1,521	)		-				(572	)
Direct expenses		65,896			1,314			7,832			38,857				113,899
Segment contribution	$	(65,896	)	$	(365	)	$	(9,353	)		(38,857	)			(114,471	)
Indirect expenses											(71,386	)	(c)		(71,386	)
Loss from operations														$	(43,085	)
(c) Components of other
Change in fair value of contingent consideration liability											(73,441	)
Change in fair value of contingent stock consideration											415
Amortization											1,640
Total other										$	(71,386	)

	Nine Months Ended September 30, 2021
	Cell Therapy			BioBanking		Degenerative Disease		Other				Total
Net sales	$	-		$	4,204	$	12,275	$	-			$	16,479
Gross profit		-			1,986		9,500		-				11,486
Direct expenses		61,082			1,499		6,765		52,453				121,799
Segment contribution	$	(61,082	)	$	487	$	2,735		(52,453	)			(110,313	)
Indirect expenses									(16,205	)	(d)		(16,205	)
Loss from operations												$	(94,108	)
(d) Components of other
Change in fair value of contingent consideration liability									(17,845	)
Amortization									1,640
Total other								$	(16,205	)